Contineum Therapeutics Inc【CTNM】株式ニュース | ADVFN

US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Contineum Therapeutics Inc (CTNM)
Contineum Therapeutics Inc (CTNM) ニュース

Contineum Therapeutics Inc (CTNM)

12.975

-0.315

( -2.37% )

更新日時： 02:17:39

個人投資家向けのプロ仕様のツール。

プレミアム

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

- Strengthened Board and management with appointments of experienced biotech leaders Troy Ignelzi, Sarah Boyce, John Healy and Kristina Haeckl...

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small...

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small...

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small...

1
2
次へ

Monksdream

Monksdream 4月前

CTNM still undecided

UpTickMeA$AP

UpTickMeA$AP 9月前

18,445,422 shares of Class A Common Stock outstanding

UpTickMeA$AP

UpTickMeA$AP 9月前

Johnson & Johnson

SHARED VOTING POWER 1,979,173

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.7%

Percentage ownership is based on 18,445,422 shares of Class A Common Stock outstanding after the closing of the Issuer’s initial public offering on April 9, 2024, as provided to the Reporting Persons by the Issuer.

https://fintel.io/doc/sec-johnson-johnson-200406-sc-13g-2024-april-10-19823-6036

Contineum Therapeutics

Sandfire Resources America

Piraeus Port Authority

Spyder Cannabis

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約